- The disease
- Alzheimer's disease (AD) is a progressive brain disorder in which nerve cells degenerate, causing memory loss and decline in thinking, language, and daily function. It is the most common cause of dementia in older adults. Mild-to-moderate AD refers to the middle stages of the disease, where symptoms are noticeable and increasingly affect independent living. There is currently no approved treatment that halts or reverses the underlying disease process, though some approved medicines modestly slow cognitive decline.
- What the asset is trying to do
- Xanamem is an oral small molecule that inhibits an enzyme called 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which produces the stress hormone cortisol inside brain cells. Elevated cortisol levels in the brain have been associated with cognitive impairment and neurodegeneration. By reducing the local production of cortisol in the brain, Xanamem is intended to lower cortisol-related stress on neurons. This approach differs from approved cholinesterase inhibitors and NMDA (N-methyl-D-aspartate) receptor antagonists, which act on neurotransmitter systems, and from recently approved anti-amyloid antibodies, which target amyloid plaques.
- What the trial is measuring, and why it matters
- The lead trial (NCT06125951) is studying the effect of 10 mg Xanamem in people with mild-to-moderate dementia due to AD (per ClinicalTrials.gov NCT06125951). The trial uses a placebo-controlled design with a target of 247 participants, and the primary completion date is October 2026 (per ClinicalTrials.gov NCT06125951). Cognitive and functional endpoints are standard in AD trials because they capture the disease domains most relevant to patients and caregivers, and are required by regulators to demonstrate clinical benefit.
- Efficacy benchmarks in this setting
- For context on the setting, approved cholinesterase inhibitors such as donepezil have shown modest slowing of cognitive decline versus placebo in mild-to-moderate AD trials, with treatment differences on the ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale) of approximately 2-3 points over six months in pivotal studies (per Rogers et al, JAMA 1998; Birks & Harvey, Cochrane Database 2018). The anti-amyloid antibody lecanemab (Leqembi) demonstrated a 27% slowing of decline on the CDR-SB (Clinical Dementia Rating - Sum of Boxes) scale versus placebo over 18 months in early AD in its Phase 3 trial (van Dyck et al, NEJM 2023). Donanemab (Kisunla) showed a 35% slowing on the iADRS (integrated Alzheimer's Disease Rating Scale) versus placebo over 76 weeks in early symptomatic AD (Sims et al, JAMA 2023). Xanamem's early-phase data are not statistically comparable to these figures, which come from larger, later-stage, differently designed trials.
- Commercial context
- The US Food and Drug Administration (FDA) has approved several treatments for AD, including cholinesterase inhibitors (donepezil, rivastigmine, galantamine), the NMDA antagonist memantine, and more recently the anti-amyloid antibodies lecanemab (Leqembi, approved 2023) and donanemab (Kisunla, approved 2024) for early AD. No 11β-HSD1 inhibitor is currently approved for any indication in the United States or Australia. Actinogen received positive scientific advice from the European Medicines Agency (EMA) in May 2026 (per ASX announcement, 27 May 2026). Actinogen completed a A$16.8 million placement and share purchase plan in February 2026 (per ASX announcement, 26 February 2026). XanaMIA (NCT06125951) appears to be Actinogen's lead clinical program based on its Phase 2/3 designation and active status (per ClinicalTrials.gov NCT06125951).